Direct thrombin inhibitors built on the azaphenylalanine scaffold provoke degranulation of mast cells

Thrombosis and Haemostasis

Volumn 95, Issue 2, 2006, Pages 294-300

  Peternel, Luka ^a,b   Štempelj, Mateja ^b   Černe, Manica ^a   Zega, Anamarija ^b   Obreza, Aleš ^b   Oblak, Marko ^a   Drevenšek, Gorazd ^b   Budihna, Metka V ^b   Stanovnik, Lovro ^b   Urleb, Uroš ^a,b  

^a Lek dd   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Azaphenylalanine scaffold; Basicity; Mast cell degranulation; Rat; Thrombin inhibitors

Indexed keywords

LK 658; LK 732; PHENYLALANINE DERIVATIVE; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

AIRFLOW; ALKALINITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CONCENTRATION RESPONSE; CONSTANTS AND COEFFICIENTS; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG FORMULATION; IN VITRO STUDY; IONIZATION; MALE; MAST CELL DEGRANULATION; MEAN ARTERIAL PRESSURE; MORTALITY; NONHUMAN; PERITONEUM MAST CELL; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; TERMINAL SEQUENCE; TRACHEA;

ANIMALS; BLOOD PRESSURE; CELL DEGRANULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; MAST CELLS; MICE; MICE, INBRED STRAINS; PHENYLALANINE; PULMONARY VENTILATION; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; SURVIVAL RATE; THROMBIN;

EID: 33645549652     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-10-0683     Document Type: Article

References (36)

1. Liebler DC, Guengerich FP. Elucidating mechanisms of drug-induced toxicity. Nat Rev Drug Discov 2005; 4: 410-20.
2. Levine MN, Raskob G, Beyth RJ et al, Hemorrhagic complications of anticoagulant treatment: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126 (Suppl): 287-310.
3. Obreza A, Stegnar M, Trampuš-Bakija A et al. Synthesis and in vitro evaluation of new azaphenylalanine derivatives as serine protease inhibitors. Pharmazie 2004; 59: 739-43.
4. Zega A, Mlinšek G, Šolmajer T et al. Thrombin inhibitors built on an azaphenylalanine scaffold, Bioorg Med Chem Lett 2004; 14: 1563-67.
5. Peternel L, Stegnar M, Drevenšek G et al. Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models. Thromb Haemost 2005; 93: 437-42.
6. Hauptmann J, Markwardt F. Pharmacologic aspects of the development of selective synthetic thrombin inhibitors as anticoagulants. Semin Thromb Hemost 1992; 18: 200-17.
7. Kaiser B, Hauptmann J, Weiss A et al. Pharmacological characterization of a new highly effective synthetic thrombin inhibitor. Biomed Biochim Acta 1985; 44: 1201-10.
8. Metcalfe DD. Effector cell heterogeneity in immediate hypersensitivity reactions. Clin Rev Allergy 1983; 1: 311-25.
9. Schwartz LB. Mast cells and basophils. Clin Allergy Immunol 2002; 16: 3-42.
10. Paton WD. Histamine release by compounds of simple chemical structure. Pharmacol Rev 1957; 9: 269-328.
11. Lagunoff D, Martin TW. Agents that release histamine from mast cells. Ann Rev Pharmacol Toxicol 1983; 23: 331-51.
12. Pearce FL. Non-IgE-mediated mast cell stimulation. Ciba Found Symp 1989; 147:74-87.
13. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997; 77: 1033-79.
14. Mousli M, Hugli TE, Landry Y et al. Peptidergic pathway in human skin and rat peritoneal mast cell activation. Immunopharmacology 1994; 27: 1-11.
15. Tharp MD, Kagey-Sobotka A, Fox CC et al. Functional heterogeneity of human mast cells from different anatomic sites: in vitro responses to morphine sulfate. J Allergy Clin Immunol 1987; 79: 646-53.
16. Theoharides TC, Askenase P. Autacoids. In: Essentials of pharmacology. Little, Brown and Company 1996; 187-215.
17. Mori K, Maru C, Takasuna K. Characterization of histamine release induced by fluoroquinolone antibacterial agents in-vivo and in-vitro. J Pharm Pharmacol 2000; 52: 577-84.
18. Macia RA, Silver AC, Gabel RA et al. Hypotension induced by vasopressin antagonists in rats: role of mast cell degranulation. Toxicol Appl Pharmacol 1990; 102: 117-27.
19. Murphy DJ, Joran ME. Respiratory and cardiovascular changes associated with toxic doses of a peptide antagonist of vasopressin in the rat. Fundam Appl Toxicol 1992; 18: 307-13.
20. Moss J. Muscle relaxants and histamine release. Acta Anaesthesiol Scand Suppl 1995; 106: 7-12.
21. Barke KE, Hough LB. Opiates, mast cells and histamine release. Life Sci 1993; 53: 1391-9.
22. Markowitz S, Saito K, Buzzi MG et al. The development of neurogenic plasma extravasation in the rat dura mater does not depend upon the degranulation of mast cells. Brain Res 1989; 477: 157-65.
23. Knudsen T, Ferjan I, Johansen T. Effect of oubain, digoxin and digitoxigenin on potassium uptake and histamine release from rat peritoneal mast cells. FEBS Lett 1993; 321: 127-31.
24. Nosal R, Slorach SA, Uvnas B. Quantitative correlation between degranulation and histamine release following exposure of rat mast cells to compound 48/80 in vitro. Acta Physiol Scand 1970; 80: 215-21.
25. Shore PA, Burkhalter A, Cohn VH. A method for the fluorometric assay of histamine in tissues. J Pharmacol Exp Ther 1959; 127: 182-6.
26. Macia RA, Gabel RA, Reginato MJ et al. Hypotension induced by growth-hormone-releasing peptide is mediated by mast cell serotonin release in the rat. Toxicol Appl Pharmacol 1990; 104: 403-10.
27. Ferry X, Brehin S, Kamel R et al. G protein-dependent activation of mast cell by peptides and basic secretagogues. Peptides 2002; 23: 1507-15.
28. Mori K, Shibano M, Satoh H et al. Differential response of mast cells separated from various organs and basophils of dogs to the fluoroquinolone antimicrobial levofloxacin. Arch Toxicol 2001; 75: 227-33.
29. Ishizaka T, Dvorak AM, Conrad DH et al. Morphologic and immunologic characterization of human basophils developed in cultures of cord blood mononuclear cells. J Immunol 1985; 134: 532-40.
30. Ebertz JM, Hermens JM, McMillan JC et al. Functional differences between human cutaneous mast cells and basophils: a comparison of morphine-induced histamine release. Agents Actions 1986; 18: 455-62.
31. Stellato C, de Paulis A, Cirillo R et al. Heterogeneity of human mast cells and basophils in response to muscle relaxants. Anesthesiology 1991; 74: 1078-86.
32. Williams PD, Laska DA, Shetler TJ et al. Vancomycin-induced release of histamine from rat peritoneal mast cells and a rat basophil cell line (RBL-1). Agents Actions 1991; 32: 217-23.
33. Mousli M, Bronner C, Landry Y et al. Direct activation of GTP-binding regulatory proteins (G-proteins) by substance P and compound 48/80. FEBS Lett 1990; 59: 260-2.
34. Bala S, Weaver J, Hastings KL. Clinical relevance of preclinical testing for allergic side effects. Toxicology 2005; 209: 195-200.
35. Lawrence ID, Warner JA, Cohan VL et al. Purification and characterization of human skin mast cells. Evidence for human mast cell heterogeneity. J. Immunol 1987; 139: 3062-9.
36. Hauptmann J. Pharmacokinetics of an emerging new class of anticoagulant/ antithrombotic drugs. A review of small-molecule thrombin inhibitors. Eur J Clin Pharmacol 2002; 57: 751-8.